HAS - CERBIOS scientific passion, respect for the client, respect for the people, is very similar between the two companies,” Angioletti said. Speed of execution is another priority. “We are now stronger and bigger, but we still maintain speed in decisionmaking and execution,” he noted. “A client recently highlighted very strongly that speed is essential to them.” Mossi echoed the sentiment, calling Swiss quality and agility “our signature worldwide.” Investing for growth To support its strategy, the group is committing significant funds. “From a technological point of view, we are investing around CHF20m (€21.4m) combined only in 2025, and other investment will follow in the five-year plan,” Mossi said. According to Angioletti, the spending reflects clear priorities: “We are expanding our R&D lab, building a second line for conjugation, and preparing for a third, expanding capacity for oncology, and expanding the R&D team for high potency in general. That’s exactly reflecting what the market is asking for.” The expansion includes strengthening quality control infrastructure, scaling manufacturing space, and upgrading industrial capabilities to ensure resilience as demand grows. That fragmentation is critical as, unlike markets dominated by a handful of giants, CDMOs remain diverse, with regional champions and niche players competing alongside multinational groups. For Mossi, this creates room for differentiated offerings. “HAS is representing a very robust scientific chemical and regulatory know-how for APIs, highly potent and anti-cancer,” he said. “Cerbios is a very solid chemical and biotechnological company. Together, the two companies represent something very unique.” Betting on ADCs Among the fastest-growing opportunities in oncology are ADCs, therapies that deliver toxic payloads directly to cancer cells via targeted antibodies. Developing them requires both advanced biotechnologies and high-potency chemistry, a rare combination. “The combination of chemical know-how and biotechnological know-how will reinforce our capacity to develop and manufacture ADC molecules,” Mossi said. In a similar vein, Angioletti added that clients are already responding: “We now have a complete set of manufacturing lines, development lines, and expertise in high potency oncology and ADCs.” The group intends to expand its ADC capabilities under the Proveo brand, which Cerbios launched with partners in 2015 to integrate conjugation, payload, and linker chemistry and fill finished. Vision and integration To support integration, the companies introduced cross-functional teams, newsletters, and staff surveys aimed at ensuring employees remain engaged and part of the new organization. “People are the basis of what we do,” Angioletti said. “They still feel part of the family, even with the changes, which is essential.” Mossi said the long-term ambition is clear. “The vision is to become a Swiss centre of excellence serving the pharmaceutical world in the CDMO sector with strong expertise in scientific content technologies and industrial sustainability.” Balancing scale with agility In an industry where projects can span a decade, both leaders stressed that customer trust and cultural alignment are vital. “Quality, Waldo Mossi, CEO of HAS Group & Denis Angioletti, Group Head of Commercial & Business Development. 25 CPHI FRANKFURT 2025 PREVIEW
RkJQdWJsaXNoZXIy MjY2OTA4MA==